Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

FASF MEMBERSHIP

August 5, 2026

Company name Shin Nippon Biomedical Laboratories, Ltd.
Representative Ryoichi Nagata, Representative Chairman, CEO
Listing TSE PRIME : ticker code 2395
Inquiries Toshiyuki Iwata, Honorary Executive Director, Head of IR & Corporate Communications
TEL +81 3 5565 6216

Notice Concerning Revisions of Consolidated Earnings Forecasts for the First Six Months of the Fiscal Year Ending March 31, 2027

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "the Company") announces the revisions of the consolidated earnings forecasts for the first six months ending September 30, 2026 (from April 1, 2026 to September 30, 2026) of the fiscal year ending March 31, 2027, previously announced on May 11, 2026, in view of the latest earnings trends.

1. Revisions of the consolidated earnings forecasts

Revisions of the consolidated earnings forecasts for the first six months of the fiscal year ending March 31, 2027
(from April 1, 2026 to September 30, 2026)

	Revenue	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecasts (A)	16,596	463	1,948	1,167	28.03
Revised forecasts (B)	17,154	1,240	2,988	1,917	46.04
Changes (B - A)	+558	+777	+1,040	+750	
Changes (%)	+3.4	+167.8	+53.4	+64.3	
ref.) Results of the fiscal year ended March 31, 2024	14,766	49	1,627	1,061	25.48

2. Reasons for the revisions

For the first six months ending September 30, 2026, we expect that the revenue will exceed the previous forecast, considering the steady performance of the CRO business. The operating profit forecast is revised upwardly due to the steady performance of the CRO business, as well as the expected timing change in recording certain business expenses in the TR business to the second half of the fiscal year. The ordinary profit is also revised upwardly, partly because foreign exchange gains of ¥172 million, which had not been anticipated in the previous forecast, were recorded in the first quarter.

The newly revised forecasts above continue to be based on the assumed exchange rate of 150.00 Japanese yen to the US dollar for the fiscal year ending March 31, 2027.

(NOTE) Financial forecasts and other statements above are based on information available as of the date of this announcement. Actual performance may differ substantially due to various factors in the future

END